Latest & greatest articles for infliximab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infliximab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infliximab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infliximab

41. Infliximab

Infliximab USE OF INFLIXIMAB IN PREGNANCY 0344 892 0909 USE OF INFLIXIMAB IN PREGNANCY (Date of issue: July 2015 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Infliximab is a chimeric human-murine IgG1 monoclonal antibody produced (...) by recombinant DNA technology. It is administered in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn’s disease and ulcerative colitis in patients where other systemic therapies are ineffective or unsuitable. Data specific to infliximab use during pregnancy are very limited. Studies investigating use during the first trimester of pregnancy of anti-TNFα therapies as a group do not suggest an increased risk of congenital malformation in exposed offspring

UK Teratology Information Service2014

42. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NE

Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NE 23908187 2014 10 07 2014 12 08 2016 11 25 1468-2060 73 11 2014 Nov Annals of the rheumatic diseases Ann. Rheum. Dis. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes (...) in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. 1954-61 10.1136/annrheumdis-2013-203497 To study whether adding initial infliximab to remission-targeted initial combination-DMARD treatment improves the long-term outcomes in patients with early rheumatoid arthritis (RA). Ninety-nine patients with early, DMARD-naïve RA were treated with a triple combination of DMARDs, starting with methotrexate (max 25 mg

EvidenceUpdates2013

43. A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease

A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease Lindsay JO, Chipperfield R, Giles A, Wheeler C, Orchard T Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study evaluated the clinical effectiveness, resource use and cost impacts infliximab for the treatment of moderate to severe Crohn's disease. The authors concluded that infliximab's effectiveness at reducing

NHS Economic Evaluation Database.2013

44. Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD)

Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD) Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD) Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD) Lansdale: HAYES, Inc.. Health Technology Brief Publication. 2013 Authors' conclusions Crohn's disease (CD) and ulcerative colitis (UC) are progressive, inflammatory disorders of the gastrointestinal tract characterized by strictures, fistulae, abdominal pain, abnormal bowel function, and rectal bleeding. CD is usually diagnosed

Health Technology Assessment (HTA) Database.2013

45. Inflectra (infliximab biosimilar) for psoriatic arthritis

Inflectra (infliximab biosimilar) for psoriatic arthritis Inflectra (infliximab biosimilar) for psoriatic arthritis Inflectra (infliximab biosimilar) for psoriatic arthritis NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Inflectra (infliximab biosimilar) for psoriatic arthritis. Birmingham: NIHR Horizon Scanning Centre

Health Technology Assessment (HTA) Database.2013

46. Inflectra (infliximab biosimilar) for ankylosing spondylitis

Inflectra (infliximab biosimilar) for ankylosing spondylitis Inflectra (infliximab biosimilar) for ankylosing spondylitis Inflectra (infliximab biosimilar) for ankylosing spondylitis NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Inflectra (infliximab biosimilar) for ankylosing spondylitis. Birmingham: NIHR Horizon

Health Technology Assessment (HTA) Database.2013

50. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. 23063316 2012 12 03 2012 12 17 2015 11 19 1474-547X 380 9857 2012 Dec 01 Lancet (London, England) Lancet Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. 1909-15 10.1016/S0140-6736(12)61084-8 S0140-6736(12)61084-8 Ciclosporin (...) and infliximab are potential rescue treatments to avoid colectomy in patients with acute severe ulcerative colitis refractory to intravenous corticosteroids. We compared the efficacy and safety of these drugs for this indication. In this parallel, open-label, randomised controlled trial, patients were aged at least 18 years, had an acute severe flare of ulcerative colitis defined by a Lichtiger score greater than 10 points, and had been given an unsuccessful course of high-dose intravenous steroids. None

EvidenceUpdates2012

51. CT-P13 (Infliximab biosimilar) for rheumatoid arthritis

CT-P13 (Infliximab biosimilar) for rheumatoid arthritis CT-P13 (Infliximab biosimilar) for rheumatoid arthritis CT-P13 (Infliximab biosimilar) for rheumatoid arthritis NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. CT-P13 (Infliximab biosimilar) for rheumatoid arthritis. Birmingham: NIHR Horizon Scanning Centre (NIHR

Health Technology Assessment (HTA) Database.2012

52. Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness

Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost (...) effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Infliximab versus methotrexate, etanercept, adalimumab, and ustekinumab for plaque psoriasis: a review of the comparative clinical efficacy, safety and cost effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Infliximab

Health Technology Assessment (HTA) Database.2012

54. The Anti-TNF Agents Entanercept and Infliximab Not Efficacious For Sjogren?s Syndrome

The Anti-TNF Agents Entanercept and Infliximab Not Efficacious For Sjogren?s Syndrome UTCAT2238, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title The Anti-TNF Agents Entanercept and Infliximab Not Efficacious For Sjogren’s Syndrome Clinical Question In patients with primary Sjogrens Syndrome, do anti-TNF agents treat oral symptoms more effectively than a placebo? Clinical Bottom Line Anti-TNF agents such as infliximab (...) and entanercept do not effectively treat symptoms in patients with primary Sjogren’s Syndrome. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Mariette/2004 103 patients with primary Sjogren’s Syndrome Randomized Controlled Trial Key results Infliximab does not relieve primary Sjogren’s Syndrome symptoms more than placebo. Active disease was measured by the visual analog scales (VAS) which evaluate joint pain

UTHSCSA Dental School CAT Library2012

55. Switch to adalimumab in patients with Crohn`s disease controlled by maintenance infliximab: prospective randomised SWITCH trial

Switch to adalimumab in patients with Crohn`s disease controlled by maintenance infliximab: prospective randomised SWITCH trial 21948942 2011 12 26 2012 02 16 2015 11 19 1468-3288 61 2 2012 Feb Gut Gut Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. 229-34 10.1136/gutjnl-2011-300755 Elective switching between anti-tumour necrosis factor (TNF) agents not necessarily dictated by efficacy or tolerability occurs (...) in clinical practice. A study was undertaken to evaluate prospectively the impact of elective switching of patients with Crohn's disease well controlled with intravenous infliximab to subcutaneous adalimumab in a controlled trial. An open-label randomised single-centre trial recruited 73 patients with ongoing response to at least 6 months of scheduled maintenance infliximab. Patients were randomised to continue intravenous 5 mg/kg infliximab or to switch to subcutaneous adalimumab 80 mg at baseline

EvidenceUpdates2012

56. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial 23196701 2013 11 05 2014 01 20 2015 11 19 1468-2060 72 12 2013 Dec Annals of the rheumatic diseases Ann. Rheum. Dis. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results (...) of the randomised, controlled, SWEFOT trial. 1927-33 10.1136/annrheumdis-2012-202062 To compare EuroQol 5-Dimensions (EQ-5D) utility and quality-adjusted life-years (QALYs) in patients with early, methotrexate (MTX) refractory rheumatoid arthritis (RA), randomised to addition of infliximab (IFX) or sulfasalazine and hydroxychloroquine (SSZ+HCQ). RA-patients with symptoms <1 year were enrolled between 2002 and 2005 at 15 Swedish centres. After 3-4 months of MTX monotherapy, patients with a remaining DAS28>3.2

EvidenceUpdates2012

57. Infliximab (Remicade) - Treatment of moderately active Crohn?s disease

Infliximab (Remicade) - Treatment of moderately active Crohn?s disease Published 10 October 2011 Statement of Advice infliximab (Remicade®) 100 mg powder for concentrate for solution for infusion (No: 739/11) Merck Sharp & Dohme Ltd 9 September 2011 ADVICE: in the absence of a submission from the holder of the marketing authorisation infliximab (Remicade®) is not recommended for use within NHS Scotland. Indication under review: Treatment of moderately active Crohn’s disease, in adult patients (...) ) multiple technology appraisal guidance No 187, infliximab is recommended as a treatment option in severe active Crohn’s disease. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does

Scottish Medicines Consortium2011

58. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis

Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis Cummins E, Asseburg C, Punekar YS, Shore E, Morris J, Briggs A, Fenwick E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the costs and health outcomes of infliximab for the treatment of adults with active and progressive psoriatic arthritis, weighing 60 to 80kg, for whom treatment with at least two disease-modifying anti-rheumatic drugs (DMARDs) had failed. The authors concluded that, infliximab was clinically effective

NHS Economic Evaluation Database.2011

59. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred

NIHR HTA programme2011

60. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose

NIHR HTA programme2011